Tesamorelin 5 mg

Tesamorelin is a synthetic peptide composed of 44 amino acids and functions as an analog for human growth hormone-releasing hormone (GHRH). It is frequently studied for its role in stimulating growth hormone (GH) secretion and its potential effects on metabolic and cellular processes.

Tesamorelin: Research Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid group added at the N-terminus to enhance stability against dipeptidyl peptidase IV (DPP-IV) degradation. It binds selectively to pituitary GHRH receptors (GHRHR) and stimulates pulsatile GH secretion through the same physiological mechanism as endogenous GHRH, preserving the natural GH pulsatility pattern.

Primary research contexts include:

• GH Axis Restoration: Tesamorelin has been studied for its ability to increase endogenous GH secretion and downstream IGF-1 levels in GH-deficient models without exogenous GH administration.
• Visceral Adiposity Research: Clinical-stage research has investigated tesamorelin's effects on visceral adipose tissue (VAT) reduction, with studies in HIV-associated lipodystrophy models demonstrating significant visceral fat modulation.
• Cognitive and Neuroprotective Research: Emerging preclinical studies are investigating the GH/IGF-1 axis in brain metabolism and neurodegenerative research, with tesamorelin as a tool peptide for axis modulation.
• Metabolic Profiling: Tesamorelin studies have examined changes in lipid metabolism, insulin sensitivity, and body composition as downstream effects of normalized GH pulsatility.

Tesamorelin is frequently compared to CJC-1295 (a longer-acting GHRH analog with DAC modification) and studied in combination in the Spartan Strong CJC + Tesamorelin blend. For storage and preparation protocols, see our guide on How to Reconstitute Peptides Safely.

Research Context: Tesamorelin in the GHRH Analog Landscape

GHRH analog research spans compounds with varying half-lives, receptor selectivities, and downstream IGF-1 induction profiles. Tesamorelin occupies a distinct position as a full-sequence GHRH analog with documented clinical research history:

• Tesamorelin — Full 44-aa GHRH analog; DPP-IV stabilized; natural pulsatility preservation; visceral fat research
• CJC-1295 + Ipamorelin — GHRH analog + GHSR-1a agonist; DAC-extended half-life; synergistic GH pulse amplification
• Spartan Strong CJC + Tesamorelin Blend — Combined GHRH formulation for comparative and cumulative GH axis research
• MOTS-c — Mitochondrial metabolic peptide; intersects with GH axis in insulin sensitivity and energy research
• NAD+ — Metabolic coenzyme; mitochondrial energy research that complements GH-axis metabolic studies

Related Research Resources

• What Are Peptides: The Complete 2026 Research Guide
• Peptide Stacking Research Guide: Synergistic Combinations
• How to Reconstitute Peptides Safely for R&D
• Quality Control in Peptide Research: Interpreting Purity
• Peptide Safety 101: Finding the Safest Place to Buy Peptides

Key Properties

Growth Hormone Stimulation:

• Investigated for its ability to bind to GHRH receptors in the pituitary gland, promoting growth hormone secretion.

Cellular Metabolism Research:

• Explored for its role in influencing lipid metabolism and fat distribution in laboratory models.

Muscle Tissue Studies:

• Studied for its effects on skeletal muscle density and tissue remodelling in controlled environments.

Applications in Research

Tesamorelin is a subject of ongoing laboratory research focusing on:

• Mechanisms of GH secretion and its downstream effects on metabolic regulation.
• Cellular processes involved in muscle development and recovery.
• Pathways influencing lipid metabolism and fat distribution.

Research is conducted in controlled laboratory settings to expand understanding of tesamorelin’s biochemical interactions and pathways. 

Storage and Handling Instructions

• Store tesamorelin in its lyophilized form at -4°F (-20°C) or lower to maintain stability.
• Protect from light, moisture, and excessive heat.
• Discard unused or reconstituted solutions immediately after use following research protocols.

Safety Information

This product is intended for research purposes. You must:

• Follow institutional and regulatory safety guidelines during handling and disposal.
• Use appropriate personal protective equipment when working with the product.
• Ensure proper disposal of unused material.

Frequently Asked Questions

What is Tesamorelin?
Tesamorelin is a synthetic peptide studied for its potential to stimulate growth hormone secretion and its effects on metabolic pathways in laboratory research.

How should Tesamorelin be stored?
Store Tesamorelin at -4°F (-20°C) in a light-protected environment. Reconstituted solutions should be used promptly following laboratory protocols.

What are the primary research focuses of Tesamorelin?
Research investigates its effects on GH secretion, lipid metabolism, and skeletal muscle development within controlled laboratory settings.

Frequently Asked Questions

What is tesamorelin and how is it classified in research?

Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of GHRH with a trans-3-hexenoic acid group attached to stabilize the molecule. In research settings, it is studied for its ability to stimulate pulsatile GH secretion and downstream IGF-1 production through GHRH receptor engagement. All laboratory and preclinical studies are conducted under controlled conditions.

What is the molecular structure of tesamorelin?

Tesamorelin has a molecular weight of approximately 5,135 Da and retains the full bioactive GHRH sequence. The trans-3-hexenoic acid modification enhances stability against dipeptidyl peptidase-IV (DPP-IV) degradation. This structural feature distinguishes tesamorelin from native GHRH and has been used to study prolonged GHRH receptor activation in preclinical and clinical research contexts.

What metabolic parameters has tesamorelin been studied for in research?

Clinical and preclinical research has investigated tesamorelin in the context of visceral adipose tissue (VAT) reduction, IGF-1 modulation, and metabolic profiling in subjects with altered fat distribution. Published randomized controlled trials have examined its effects on body composition markers in controlled clinical research settings.

How should tesamorelin be stored in a research environment?

Lyophilized tesamorelin should be stored at 2-8 degrees C (refrigerated), protected from light, and reconstituted with sterile water for injection immediately before use in the research protocol. Once reconstituted, the solution should be used promptly. Extended storage of reconstituted peptide is not recommended to maintain structural stability.

What purity standards are expected for research-grade tesamorelin?

Research-grade tesamorelin should achieve greater than or equal to 98% purity as confirmed by HPLC analysis, with identity verification by mass spectrometry. Certificates of Analysis (in-house testing) from qualified laboratories should accompany each batch. Researchers should verify purity and batch documentation before initiating experimental protocols.

What distinguishes tesamorelin from other GHRH analogs in preclinical research?

Tesamorelin's trans-3-hexenoic acid modification provides extended half-life compared to native GHRH, enabling more stable and reproducible experimental conditions in research protocols. Unlike synthetic GH secretagogues, tesamorelin acts through the natural GHRH receptor pathway, making it a useful research tool for studying the somatotropic axis under physiologically relevant conditions.

References

1. Falutz J, Potvin D, Mamputu JC, et al. “Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.” J Acquir Immune Defic Syndr. 2010;53(3):311-22.. PubMed
2. Stanley TL, Falutz J, Marsolais C, et al. “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.” Clin Infect Dis. 2012;54(11):1642-51.. PubMed
3. Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” Drugs. 2011;71(8):1071-91.. PubMed
4. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.” PLoS One. 2015;10(10):e0140358.. PubMed